nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Clinical Ovarian … & Other Gynecologic Cancer Too!
|
Allen, David M. |
|
2011 |
4 |
2 |
p. 53- 1 p. |
artikel |
2 |
CON: Not All Patients With Endometrial Cancer With Extrauterine Disease Should Receive Chemotherapy After Any Indicated Surgery
|
Randall, Marcus E. |
|
2011 |
4 |
2 |
p. 66-69 4 p. |
artikel |
3 |
CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
|
Eisenhauer, Eric L. |
|
2011 |
4 |
2 |
p. 111-113 3 p. |
artikel |
4 |
CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening
|
McNally, Thomas P. |
|
2011 |
4 |
2 |
p. 86-89 4 p. |
artikel |
5 |
CON: Patients With Metastatic/Recurrent Cervical Cancer Should Not be Treated With Cisplatin Plus Paclitaxel
|
Thigpen, J. Tate |
|
2011 |
4 |
2 |
p. 94-96 3 p. |
artikel |
6 |
CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy
|
Sabbatini, Paul |
|
2011 |
4 |
2 |
p. 74-76 3 p. |
artikel |
7 |
CON: Secondary Surgical Debulking is Not an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
|
Thigpen, J. Tate |
|
2011 |
4 |
2 |
p. 80-82 3 p. |
artikel |
8 |
CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin
|
Thigpen, J. Tate |
|
2011 |
4 |
2 |
p. 101-105 5 p. |
artikel |
9 |
CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
|
Farley, John |
|
2011 |
4 |
2 |
p. 57-61 5 p. |
artikel |
10 |
Editorial Board
|
|
|
2011 |
4 |
2 |
p. A1- 1 p. |
artikel |
11 |
PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
|
Boren, Todd P. |
|
2011 |
4 |
2 |
p. 106-110 5 p. |
artikel |
12 |
PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening
|
Karlan, Beth Y. |
|
2011 |
4 |
2 |
p. 83-85 3 p. |
artikel |
13 |
PRO: Patients With Endometrial Carcinoma Involving Extrauterine Disease Should, After Any Indicated Surgery, Receive Chemotherapy
|
Thigpen, J. Tate |
|
2011 |
4 |
2 |
p. 62-65 4 p. |
artikel |
14 |
PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel
|
Tewari, Krishnansu S. |
|
2011 |
4 |
2 |
p. 90-93 4 p. |
artikel |
15 |
PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
|
Boruta, David |
|
2011 |
4 |
2 |
p. 70-73 4 p. |
artikel |
16 |
PRO: Secondary Surgical Debulking is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
|
Nagel, Christa I. |
|
2011 |
4 |
2 |
p. 77-79 3 p. |
artikel |
17 |
PRO: Systemic Therapy for All Endometrial Cancers Should be Paclitaxel Plus Carboplatin
|
Powell, Matthew A. |
|
2011 |
4 |
2 |
p. 97-100 4 p. |
artikel |
18 |
PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay
|
Thigpen, J. Tate |
|
2011 |
4 |
2 |
p. 54-56 3 p. |
artikel |
19 |
Table of Contents
|
|
|
2011 |
4 |
2 |
p. A2-A3 nvt p. |
artikel |